Abstract
Purpose: Mesenchymal stromal cells (MSCs) have been investigated as a therapy for osteoarthritis (OA), including a pioneering first-in-Canada clinical trial run by our laboratory using intra-articular injections of autologous bone marrow-derived MSCs. The Results of our trial showed that the MSCs acted predominantly through anti-inflammatory and anti-fibrotic mechanisms and reduced the fraction of pro-inflammatory monocytes in the OA synovial fluid. Despite this success, insufficient potency and/or MSC donor heterogeneity can limit the efficacy of intra-articular MSC injections for some patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
